Shilpa Medicare Ltd has received a warning letter from US FDA for its Jadcherla facility, Telangana.The company said that it will be engaging with the agency and are fully committed in resolving this issue at the earliest.The company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility.The company currently has three manufacturing facilities approved by US FDA - One formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the US FDA at this point of time.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!